629 Shares in Medpace Holdings, Inc. (NASDAQ:MEDP) Purchased by 180 Wealth Advisors LLC

180 Wealth Advisors LLC purchased a new position in Medpace Holdings, Inc. (NASDAQ:MEDP) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 629 shares of the company’s stock, valued at approximately $209,000.

Several other hedge funds have also recently added to or reduced their stakes in the business. Wealth Alliance raised its position in Medpace by 2.9% in the second quarter. Wealth Alliance now owns 970 shares of the company’s stock worth $399,000 after purchasing an additional 27 shares in the last quarter. Centaurus Financial Inc. raised its position in Medpace by 2.0% in the third quarter. Centaurus Financial Inc. now owns 1,513 shares of the company’s stock worth $505,000 after purchasing an additional 29 shares in the last quarter. Lindenwold Advisors INC raised its position in Medpace by 1.6% in the third quarter. Lindenwold Advisors INC now owns 2,026 shares of the company’s stock worth $676,000 after purchasing an additional 32 shares in the last quarter. M&T Bank Corp raised its position in Medpace by 1.2% in the third quarter. M&T Bank Corp now owns 3,199 shares of the company’s stock worth $1,068,000 after purchasing an additional 37 shares in the last quarter. Finally, Nations Financial Group Inc. IA ADV raised its position in Medpace by 1.7% in the third quarter. Nations Financial Group Inc. IA ADV now owns 2,376 shares of the company’s stock worth $793,000 after purchasing an additional 39 shares in the last quarter. Institutional investors and hedge funds own 77.98% of the company’s stock.

Analyst Ratings Changes

Several analysts have weighed in on MEDP shares. Truist Financial decreased their price objective on shares of Medpace from $415.00 to $397.00 and set a “hold” rating on the stock in a research note on Monday, October 14th. UBS Group cut shares of Medpace from a “buy” rating to a “neutral” rating and decreased their price objective for the stock from $420.00 to $350.00 in a research note on Friday, September 27th. Redburn Atlantic started coverage on shares of Medpace in a research note on Monday, October 14th. They set a “buy” rating and a $404.00 price objective on the stock. Robert W. Baird upped their price objective on shares of Medpace from $349.00 to $354.00 and gave the stock a “neutral” rating in a research note on Monday, November 25th. Finally, William Blair reaffirmed an “outperform” rating on shares of Medpace in a research note on Tuesday, October 22nd. Seven research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $380.56.

Medpace Price Performance

MEDP opened at $335.23 on Thursday. Medpace Holdings, Inc. has a one year low of $277.72 and a one year high of $459.77. The company’s 50 day simple moving average is $341.36 and its 200-day simple moving average is $358.26. The stock has a market capitalization of $10.42 billion, a P/E ratio of 29.35, a price-to-earnings-growth ratio of 1.91 and a beta of 1.36.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings data on Monday, October 21st. The company reported $3.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.77 by $0.24. Medpace had a net margin of 17.66% and a return on equity of 50.87%. The firm had revenue of $533.32 million for the quarter, compared to analysts’ expectations of $540.99 million. During the same period last year, the firm earned $2.22 earnings per share. The business’s revenue for the quarter was up 8.3% on a year-over-year basis. As a group, analysts anticipate that Medpace Holdings, Inc. will post 11.93 EPS for the current year.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.